Context Therapeutics Inc. (CNTX): Price and Financial Metrics


Context Therapeutics Inc. (CNTX): $2.05

-0.03 (-1.44%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CNTX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

CNTX Stock Price Chart Interactive Chart >

Price chart for CNTX

CNTX Price/Volume Stats

Current price $2.05 52-week high $10.87
Prev. close $2.08 52-week low $1.27
Day low $2.00 Volume 119,400
Day high $2.10 Avg. volume 396,385
50-day MA $1.85 Dividend yield N/A
200-day MA $0.00 Market Cap 32.73M

Context Therapeutics Inc. (CNTX) Company Bio


Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a selective potent antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as ovarian, uterine (endometrial), and breast cancers. The company also engages in developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. In addition, it is involved in the development of Sigma1, a cellular protein that regulates homeostasis, which is in clinical studies for the treatment of breast and prostate cancer. Context Therapeutics Inc. has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of CLDN6xCD3 bsAb. The company was founded in 2015 and is based in Philadelphia, Pennsylvania.


CNTX Latest News Stream


Event/Time News Detail
Loading, please wait...

CNTX Latest Social Stream


Loading social stream, please wait...

View Full CNTX Social Stream

Latest CNTX News From Around the Web

Below are the latest news stories about Context Therapeutics Inc that investors may wish to consider to help them evaluate CNTX as an investment opportunity.

Context Therapeutics® Strengthens Research & Development Team

Company names Christopher Beck as SVP, Operations and Mark Fletcher, Ph.D., as VP, R&DPHILADELPHIA, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, today announced the appointments of Christopher Beck as SVP of Operations and Mark Fletcher, Ph.D., as VP of R&D. Context also announced the planned retirement of its current

Yahoo | January 5, 2022

Context Therapeutics® to Participate in Two January 2022 Investor Conferences

PHILADELPHIA, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, today announced that Chief Executive Officer Martin Lehr will participate virtually in two investor conferences in January 2022. Details of the events are as follows: Biotech Showcase™ 2022: The company’s presentation will be available for on-demand viewing dur

Yahoo | January 4, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

We've reached the halfway point of the week and we're starting it with an overview of the biggest pre-market stock movers for Wednesday!

William White on InvestorPlace | December 22, 2021

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Welcome back, investor!

William White on InvestorPlace | December 13, 2021

CNTX Stock: The Breast Cancer Clinical Trial Data That Has Context Therapeutics Soaring Today

Context Therapeutics (CNTX) stock is rising higher on Friday thanks to results from a Phase 0 breast cancer clinical trial.

William White on InvestorPlace | December 10, 2021

Read More 'CNTX' Stories Here

CNTX Price Returns

1-mo 42.36%
3-mo 14.53%
6-mo -63.26%
1-year N/A
3-year N/A
5-year N/A
YTD -22.93%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5036 seconds.